Tag: JWST

  • [Science] Possible New Dwarf Planet Beyond Pluto Found in Rubin Observatory Data

    [Science] Possible New Dwarf Planet Beyond Pluto Found in Rubin Observatory Data

    Astronomers using data from the Vera C. Rubin Observatory have identified an object called 2026 ED138, currently about 46 times farther from the Sun than Earth is and perhaps 600 to 1,500 kilometers across — large enough that it may qualify as the solar system’s sixth dwarf planet. It matters because it shows that sizable worlds can still hide in the outer solar system, and that new survey data and search software are now able to dig them out.

    原論文情報 / Original Paper
    Announcement: Possible new dwarf planet 2026 ED138 (provisional designation)
    Announced by: NSF–DOE Vera C. Rubin Observatory / NOIRLab, October 27, 2026
    Discoverer: Matthew Holman, Center for Astrophysics | Harvard & Smithsonian
    Peer-reviewed paper: none cited in the coverage we checked. Source: University of Washington News

    What the team found

    The object carries the provisional name 2026 ED138. It was first identified on the evening of October 13, 2026, by astronomer Matthew Holman of the Center for Astrophysics | Harvard & Smithsonian, who was sifting through images that the NSF–DOE Vera C. Rubin Observatory had collected earlier this year; the University of Washington describes that data as preliminary. The object had been photographed before, but never recognized as a single moving body. Holman developed the search code together with colleague Kevin Napier. It links billions of detections of moving objects to work out which ones belong to the same body. Holman has described his first reaction as “excited disbelief,” and he immediately checked whether he or the code had made a mistake.

    Once the candidate was in hand, more data fell into place. According to Space.com and Universe Today, Rubin’s telescope recorded it 30 times on 20 nights between March 4 and July 11, 2026. Mario Jurić of the University of Washington, who leads Rubin’s solar system team, turned up additional detections in the catalog. Archival images from other surveys, including the Dark Energy Camera on a 4-meter telescope in Chile, extend the record back to 2016. That gives the team more than a decade of positions from which to calculate the orbit.

    Where it was hiding

    ED138 is currently about 46 astronomical units from the Sun (one astronomical unit is the Earth–Sun distance), compared with about 40 for Pluto on average. Its orbit is tilted roughly 25 degrees from the plane in which the planets travel, a tilt Space.com says likely stems from a gravitational interaction with Neptune. Universe Today describes it as a “hot classical” object, a label for icy Kuiper belt bodies on more tilted, disturbed orbits.

    The location also helps explain why it was missed. ED138 lies in a region near the plane of our own galaxy, where the Milky Way’s dense star field makes faint, slowly moving dots hard to pick out. The University of Washington’s write-up says this likely hid it from most other telescopes. Finding it took both Rubin’s repeated imaging and software built to link scattered faint detections. We covered a similar story of patient, data-driven discovery in our earlier piece on a possible hidden pair of supermassive black holes.

    How big is it, really?

    The headline estimate is 600 to 1,500 kilometers across. That would put ED138 anywhere from a modest icy world, smaller than Ceres, up to one comparable to the dwarf planet Makemake, which is about 1,430 km wide according to The Planetary Society. Jurić has put the best guess near 1,000 km and, as Gizmodo reports, called it the largest trans-Neptunian object found in about 20 years. Those figures remain estimates.

    Bar chart comparing the estimated 600 to 1,500 km size of 2026 ED138 with Ceres, Makemake, Eris and Pluto
    Estimated size of 2026 ED138 compared with known dwarf planets. Sources: UW News, Space.com, Gizmodo (ED138 estimate); The Planetary Society (others).

    Why such a wide range? Telescopes see reflected sunlight, and how much light arrives depends on two things at once: how big the object is and how reflective its surface is (its albedo). A small, shiny body and a large, dark body can look equally bright from far away. The team estimated size from distance, brightness and an assumed surface reflectivity, so the range mostly reflects uncertainty about that reflectivity. A 2.5-fold gap in diameter corresponds to roughly a six-fold gap in albedo.

    Schematic of a small reflective body and a large dark body appearing equally bright
    Schematic: the same brightness can come from a small, reflective object or a large, dark one. Created by Xsciens.

    What counts as a dwarf planet

    NASA summarizes the International Astronomical Union’s definition: a dwarf planet orbits the Sun, is massive enough for its own gravity to pull it into a nearly round shape, has not cleared the neighborhood around its orbit, and is not a moon. Five objects are recognized today: Ceres, Pluto, Eris, Haumea and Makemake. If ED138 is confirmed to meet the criteria and is formally recognized, it would be the sixth.

    Roundness is why size matters so much. The University of Washington’s write-up notes that icy bodies of this scale are expected to be round, but nobody has yet observed ED138 well enough to see its shape. Until its diameter and shape are measured, “candidate” is the accurate word.

    What happens next

    Follow-up work will aim to pin down the size. Space.com reports that this requires infrared observations, naming the James Webb Space Telescope, because an object’s heat emission helps separate its size from its reflectivity. Meanwhile, Rubin’s ten-year survey of the southern sky, which began in June 2026, continues, and searches of older images — “precovery,” in Jurić’s term, meaning finding an object in images taken before anyone recognized it — may turn up more objects earlier surveys missed.

    In the coverage we checked, no peer-reviewed paper accompanies the announcement, so the numbers above should be read as the team’s preliminary estimates.

    Xsciens Editorial Note

    This is a candidate, not a confirmed dwarf planet: its orbit is calculated from about a decade of positions, but its size is still an estimate.

    • Observed versus calculated. What astronomers recorded directly were positions and brightness in many images. The distance (about 46 au) and the orbital tilt (about 25°) are calculated from them, and the 600–1,500 km diameter is a further estimate that also assumes how reflective the surface is, which is why the range spans a factor of 2.5.
    • Limits. Roundness has not been observed, and the coverage we reviewed cites no peer-reviewed paper. This note rests on the announcement and secondary coverage; we could not open the NOIRLab release itself. “Hot classical” is Universe Today’s description, for a category of Kuiper belt objects defined by widely tilted orbits.
    • What to watch. Infrared measurements of its size, for which Space.com points to the James Webb Space Telescope, and whether the object is formally recognized as a dwarf planet.
    • From the editors — the solar-system poster on a classroom wall may soon need a new line. If Rubin keeps scanning the southern sky for ten years, more faint worlds could plausibly turn up, ones that hid in crowded star fields or slipped between older surveys. The catch is that “candidate” is the operative word, and until the size is measured the headline number could move a lot. So treat 1,000 km as a placeholder, and look again when the infrared measurements arrive.

    References for this note: NASA, What is a planet?, Müller et al., Trans-Neptunian objects and Centaurs at thermal wavelengths (arXiv), Petit et al., Canada-France Ecliptic Plane Survey (arXiv)

    Sources: University of Washington News, Space.com, Universe Today, Gizmodo, The Planetary Society

  • [Science] Scientists Get Cancer Cells to Make Their Own Chemo Drug — Lab Tests Suggest a Way to Spare Healthy Tissue

    [Science] Scientists Get Cancer Cells to Make Their Own Chemo Drug — Lab Tests Suggest a Way to Spare Healthy Tissue

    Much of chemotherapy’s toll on the body comes from the fact that the drug attacks healthy, fast-dividing cells right along with cancerous ones. A team from RIKEN and Institute of Science Tokyo has developed a way around that: instead of administering an active drug, they deliver an inert precursor that only turns into a cancer-fighting compound once it is inside a cell, using carbon monoxide (CO) — a metabolite that runs elevated in some cancer cells — as the raw material. In effect, the cancer cell is enlisted to manufacture its own drug from a harmless precursor, while cells with lower CO output make far less of it. It’s an early-stage, cell-culture result rather than a ready-made treatment: the researchers themselves describe the selectivity they observed as modest, and animal or human safety data don’t yet exist.

    原論文情報 / Original Paper
    Title: Harnessing endogenous carbon monoxide for cancer-selective drug synthesis
    Authors: Kawai, M. et al.
    Journal: Nature Communications 17, 9603 (2026)
    DOI: 10.1038/s41467-026-77616-8

    A palladium catalyst smuggled in by the body’s own protein

    The team built what they call an albumin-palladium complex: a palladium catalyst tucked into a hydrophobic pocket of human serum albumin, the most abundant protein in blood. A small anchor molecule steers the complex to albumin’s drug-binding site, and this packaging keeps the catalyst active even in the presence of glutathione, an abundant cellular antioxidant that would normally deactivate a bare palladium compound. Once inside a cell, the complex reacts with intracellular CO to assemble a phenanthridinone-scaffold compound with topoisomerase-I-inhibiting activity — a mechanism shared with established anticancer drugs. The approach flips the usual order of drug delivery: rather than making a drug and shipping it to the cell, the team ships an inert precursor and lets the cell’s own CO serve as the building material for the final compound, assembled on site.

    Bar chart comparing CO-derived drug production across four cancer cell lines and one normal cell line
    Source: created from data in Kawai et al. (2026), Nature Communications 17, 9603

    Up to ninefold more compound formed in cancer cells

    According to the paper, after 48 hours in culture, the amount of CO-derived compound produced in four cancer cell lines — liver (HepG2), cervical (HeLa S3), breast (MCF7), and lung (A549) — was up to roughly ninefold higher than in normal fibroblasts (TIG3): 136 picomoles per million cells for the lung line versus 15 picomoles for the normal one. In the liver cancer line, the concentration needed to be effective (IC50) was 13.99 micromolar, about a third of the 37.54 micromolar needed against normal fibroblasts. In breast cancer cells, RIKEN’s release reports that treatment at 5 to 10 micromolar significantly suppressed colony formation over 12 days, with near-complete inhibition at 10 micromolar and above.

    After 48 hours, lung cancer cells used CO to synthesize roughly nine times as much of the drug compound as normal fibroblasts did.

    A new chemical angle on reducing chemotherapy’s toll

    The researchers frame this as an early step toward a broader drug-design strategy: using disease-specific metabolites, not just in cancer, as the raw material for synthesizing therapeutics inside the body rather than merely as diagnostic markers. The comparisons so far involve one cancer cell line and one normal cell line at a time, and the work is limited to cultured cells — animal and clinical studies still lie ahead. Still, it offers a new chemical approach to the long-standing challenge of designing cancer treatments that spare healthy tissue.

    The study was published on September 17, 2026, in Nature Communications.

    Xsciens editorial note: what the numbers do and do not show

    The most striking figure is the up to ninefold difference in how much compound the cells made, with lung cancer cells producing 136 picomoles against 15 picomoles in normal fibroblasts. But that is a measure of synthesis inside cells, not of tumor shrinkage. The effective concentration (IC50) in liver cancer cells, 13.99 micromolar versus 37.54 micromolar in normal fibroblasts, is about a third, so the selectivity in killing cells is real but more modest than the ninefold synthesis gap suggests.

    It is also worth noting how the idea differs from conventional targeted drugs. Those aim at a molecule on or in the cancer cell. Here, a harmless precursor is delivered first and the cancer cell’s own metabolism supplies carbon monoxide as a building block, so the strategy depends on how much CO a given tumor makes. The comparisons so far use single cell lines in culture, so how well this works in tumors made of mixed cells, and whether enough precursor can reach them, are open questions for animal and clinical studies.

    Key terms

    • Albumin: the most abundant protein in blood, here used as a carrier for the catalyst
    • Palladium complex: a compound of the metal palladium that acts as a catalyst, speeding up a chemical reaction
    • Glutathione: an antioxidant present in large amounts in cells that can deactivate many catalysts
    • Topoisomerase I inhibitor: a drug that blocks an enzyme cells need to copy DNA, a mechanism used by established anticancer drugs
    • IC50: the concentration of a compound needed to reduce cell growth by half

    Sources: RIKEN, Kawai et al., Nature Communications 17, 9603 (2026), Tech & Bio Life Sciences